In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

REGN stock has seen an impact that was slightly ... as evident in HQ Portfolio performance metrics. The views and opinions expressed herein are the views and opinions of the author and do not ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

On Monday, Truist Securities analysts reiterated their Buy rating for Regeneron Pharma (NASDAQ: NASDAQ:REGN) stock, maintaining ... lack of clarity on subgroup performance in the study.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) faced a turbulent week as its shares plunged 17%, despite announcing encouraging results from a Phase 3 trial of itepekimab for chronic obstructive ...

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

Access Regeneron Pharma stock price history with daily data, historical ... This page offers a complete view of REGN stock history, enabling you to study performance over specific time frames.

Regeneron Pharmaceuticals just hit a new 52-week low after UBS dropped its price target and slapped on a neutral rating.

Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

noting the lack of clarity on subgroup performance in the study. This uncertainty, combined with ongoing headwinds for Eylea, contributes to the expectation of sideways trading for Regeneron stock in ...

Get the latest news on Regeneron Pharmaceuticals stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Regeneron Pharmaceuticals performance ...